Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 15,175 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亚州诺瓦托，2024年12月20日（环球新闻稿）-- Ultragenyx Pharmaceutical Inc.（纳斯达克：RARE）是一家专注于开发和商业化新型罕见病和超罕见病疗法的生物制药公司，今天报告向15名新聘用的非执行官授予15,175个受限制的股票单位。该奖励已获得公司董事会薪酬委员会的批准，并根据Ultragenyx员工诱导计划授予，授予日期为2024年12月16日，以作为新员工根据纳斯达克上市规则5635(c)(4)与Ultragenyx签订雇佣协议的诱因。
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
这些受限制的股票单位将在四年内逐渐归属，授予日期每周年的25%基本股份归属，前提是员工在该归属日期持续为公司工作。
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
关于Ultragenyx Pharmaceutical Inc.
Ultragenyx是一家生物制药公司，致力于为患者提供新型产品，以治疗严重的罕见和超罕见遗传疾病。该公司建立了一个多样化的已批准疗法和产品候选者组合，旨在解决具有高未满足医疗需求和明确治疗生物的疾病，通常这些疾病没有批准的疗法来治疗其根本原因。
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
该公司由一支有丰富罕见病治疗药物开发和商业化经验的管理团队领导。Ultragenyx 的策略基于及时高效的药品研发，旨在以最大的紧迫性向患者提供安全有效的治疗。
For more information on Ultragenyx, please visit the company's website at: .
欲了解更多有关Ultragenyx的信息，请访问公司的官方网站：。
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
联系Ultragenyx Pharmaceutical
投资者与媒体
约书亚·比嘉
(415) 475-6370
